<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31760">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882218</url>
  </required_header>
  <id_info>
    <org_study_id>12.0262</org_study_id>
    <nct_id>NCT01882218</nct_id>
  </id_info>
  <brief_title>Direct Peritoneal Resuscitation Plus Conventional Resuscitation</brief_title>
  <official_title>A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if direct peritoneal resuscitation (DPR) (putting a
      sugar solution into the abdominal cavity) helps blood flow through vital organs in the body
      that may suffer from low blood flow due to  surgery.  We will also try to find out if the
      DPR will help patients recover faster from liver surgery.  Lastly, this study will also try
      to find if direct peritoneal resuscitation decreases levels of signaling chemicals in the
      blood called 'cytokines' and a protein called high-mobility group protein 1, which is known
      to cause tissue damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study will focus on 108 patients requiring hepatic resection for colorectal cancer
      metastasis or primary hepatocellular carcinoma.  These patients will then be randomized into
      two 54 patient arms: the control arm of conventional resuscitation only and the experimental
      arm of conventional resuscitation with DPR immediately post operatively.  Patient exclusion
      criteria will be: 1) unable to obtain proper consent for enrollment, 2) age less than 18
      years or greater than 75 years, 3) chronic renal failure, cirrhosis, or congestive heart
      failure, 4) patients requiring portal venous embolization prior to resection, or 5) women
      who are pregnant or lactating/breast feeding.  A pregnancy test (urine or blood) will be
      done for female subjects of child bearing potential the day prior or the morning of surgery
      per the usual standard of care pre-op labs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Hepatic Cancer</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard liver surgery and post-operative treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galactose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galactose</intervention_name>
    <description>After surgery, galactose will be dripped into the belly for up to 24 hours after surgery</description>
    <arm_group_label>Galactose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Treatment</intervention_name>
    <description>Standard liver surgery.</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colorectal cancer

          -  Scheduled for liver resection

          -  18 to 75

        Exclusion Criteria:

          -  Chronic renal failure

          -  Cirrhosis

          -  Congestive heart failure

          -  Requiring portal venous embolization prior to resection

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Smith, MD</last_name>
      <phone>502-852-1895</phone>
      <email>j0smit19@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly McMasters, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rob Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Scoggins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Smith, MD</last_name>
      <phone>502-852-5675</phone>
      <email>j0smit19@louisville.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 17, 2013</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Jason Smith</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Liver cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
